MTOR and breast carcinoma: To re-evaluate the clinical impacts of the PI3K/AKT/mTOR pathway on anti-HER2 therapy pathway, we conducted a retrospective analysis using clinical data from patients with HER2+ breast cancer who had received anti-HER2 therapies (Fig. 1).